Latest News

LEO Pharma will acquire worldwide rights to dersimelagon, an investigational oral therapy under FDA review for EPP and XLP.

In the August letter from the editor in chief, Christopher Bunick, MD, PhD, explains bemotrizinol’s broad-spectrum UVA/UVB benefits and simple UV safety habits for sunscreen, pools, and wounds.

Social media skin care trends drive excess product use, skin barrier damage, delayed dermatologist visits, and worse acne—especially among TikTok and influencer-following users.

Our August issue tackles psoriasis, acne, aesthetics, sunscreen safety, and more.

Oral peptide pills are reshaping psoriasis care, from semaglutide breakthroughs to IL‑23 blocker icotrokinra—here's what dermatologists need to know now.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.

Are pimple patches really that effective in clearing acne or is it just a myth? Read more about the latest social media trend and learn how to counsel your patients in the clinic.

Review 10 evidence-based answers on GPP pathophysiology, diagnosis, and IL-36-targeted management, drawn from National Psoriasis Foundation consensus and emergency medicine literature.

Persistent hives with throat tightness and abdominal pain suggest C1‑INH deficiency in chronic spontaneous urticaria—see when complement tests point to HAE.

At a Dermatology Times Case-Based Roundtable in Las Vegas, clinicians compared topical corticosteroids, newer nonsteroidal agents, and systemic therapy across adult and adolescent AD cases.

This review of the latest dermatological studies includes insights on JAKs in severe HS, reactive cutaneous capillary endothelial proliferation in esophageal SCC, PN treatment preferences, and more.

Envudeucitinib achieved PASI 100 in 54% of continuously treated patients at 48 weeks in the phase 3 ONWARD3 extension study.

See how precision biologics—dupilumab, IL-13/IL-31 blockers, JAK inhibitors, and omalizumab—change treatment for atopic dermatitis and chronic spontaneous urticaria.